Estella Matutes

Q: What Schools Are Affiliated With Estella Matutes

Estella Matutes is affiliated with the following schools: Institute of Cancer Research, University of Oxford, University of Birmingham, University of Barcelona

Estella Matutes's AcademicInfluence.com Rankings

Estella Matutes

Biology

#12801

World Rank

#16302

Historical Rank

Immunology

#861

World Rank

#884

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Estella Matutes Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Estella Matutes's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). (1995) (1451)
The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. (1994) (816)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial (2007) (592)
Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. (1991) (423)
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia (2008) (380)
High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. (2001) (302)
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. (2003) (290)
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. (2011) (271)
Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. (2011) (261)
Common variants at 2q37.3, 8q24.21, 15q21.3, and 16q24.1 influence chronic lymphocytic leukemia risk (2010) (243)
Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. (2002) (234)
Acute myeloid leukaemia with recurrent genetic abnormalities. . (2001) (230)
Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. (1998) (224)
Definition of acute biphenotypic leukemia. (1997) (213)
Long‐term follow‐up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis (2009) (213)
Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. (1997) (200)
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. (2012) (184)
The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. (1994) (183)
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10 (2011) (181)
Outcome of biphenotypic acute leukemia. (1999) (171)
Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases (1991) (170)
The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). (1998) (162)
Acute leukaemias of ambiguous lineage. . (2001) (159)
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia (2004) (154)
The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. (1994) (150)
Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia (1997) (145)
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia (2012) (139)
Cutaneous findings in chronic lymphocytic leukaemia (2004) (136)
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. (2012) (133)
Cytogenetic studies in splenic lymphoma with villous lymphocytes (1993) (132)
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation (2010) (130)
Familial chronic lymphocytic leukaemia: a survey and review of published studies (2000) (130)
Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients (2003) (129)
Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cellsPREPARED BY THE CD34+ HAEMATOPOIETIC STEM CELL WORKING PARTY* (1999) (128)
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing (2015) (122)
Morphological and immunophenotypic features of chronic lymphocytic leukemia. (2000) (120)
The variant form of hairy-cell leukaemia. (2003) (120)
Effect of Lamivudine on Human T-Cell Leukemia Virus Type 1 (HTLV-1) DNA Copy Number, T-Cell Phenotype, and Anti-Tax Cytotoxic T-Cell Frequency in Patients with HTLV-1-Associated Myelopathy (1999) (115)
Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. (2005) (113)
Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. (2002) (113)
High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities (2003) (111)
p53 abnormalities in B-cell prolymphocytic leukemia. (1997) (110)
The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. (2004) (110)
Megakaryoblastic leukemia presenting as acute myelofibrosis -- a study of four cases with the platelet-peroxidase reaction (1981) (110)
The natural history and clinico-pathological features of the variant form of hairy cell leukemia (2001) (109)
p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis (1997) (108)
Long remissions in hairy cell leukemia with purine analogs (2005) (108)
Lineage commitment in biphenotypic acute leukemia. (1993) (107)
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. (2007) (99)
Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12 (1997) (97)
Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin D1 gene. (1994) (96)
ATM is usually rearranged in T-cell prolymphocytic leukaemia (1998) (96)
Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. (2005) (95)
Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects (2006) (94)
T‐cell large granular lymphocyte leukemia (2006) (93)
Differential expression of CD3 and CD7 in T‐cell malignancies: a quantitative study by flow cytometry (1996) (88)
Long‐term follow‐up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine (1999) (88)
Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases (2012) (84)
Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. (1999) (84)
Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. (2012) (81)
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. (2002) (81)
A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. (2005) (80)
Immunophenotyping and differential diagnosis of hairy cell leukemia. (2006) (77)
Delineation of the minimal region of loss at 13q14 in multiple myeloma (2003) (77)
Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients (2001) (76)
Recurrent CDKN1B (p27) mutations in hairy cell leukemia. (2015) (75)
Prospective study of HTLV-I infection in an initially asymptomatic cohort. (1999) (75)
Impact of immunophenotyping on management of acute leukemias. (1999) (73)
Detection of minimal residual disease in B‐lineage acute lymphoblastic leukaemia by quantitative flow cytometry (1998) (71)
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. (2011) (71)
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review (2004) (70)
T‐cell malignancies in Brazil. Clinico‐pathological and molecular studies of HTLV‐I‐positive and ‐negative cases (1995) (69)
Disease Features in Acute Myeloid Leukemia with t(8;21)(q22;q22). Influence of Age, Secondary Karyotype Abnormalities, CD19 Status, and Extramedullar Leukemia on Survival (2000) (69)
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma (2012) (68)
B‐prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia (2004) (68)
Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features (2010) (67)
ζ‐Chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia (2005) (67)
The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. (2005) (66)
Mycosis fungoides and Sezary syndrome are not associated with HTLV‐I infection: an international study (1997) (64)
Primary Bone Marrow Lymphoma: An Uncommon Extranodal Presentation of Aggressive Non-Hodgkin Lymphomas (2012) (63)
High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy (2008) (63)
Alemtuzumab in T-cell malignancies (2002) (61)
The t(14;19)(q32;q13)‐positive small B‐cell leukaemia: a clinicopathologic and cytogenetic study of seven cases (2007) (61)
Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia/lymphoma. (2011) (61)
Long term results with 2'deoxycoformycin in hairy cell leukemia. (1994) (60)
Stem cell transplantation after alemtuzumab in T‐cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study (2010) (60)
The Leukemic Presentation of Mantle-cell Lymphoma: Disease Features and Prognostic Factors in 58 Patients (2004) (59)
Causation of chronic lymphocytic leukemia--insights from familial disease. (2003) (58)
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1- mantle cell lymphoma. (2019) (57)
Diagnostic significance of CD20 and FMC7 expression in B-cell disorders. (2003) (57)
Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. (2004) (56)
Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. (2004) (56)
The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia (1997) (55)
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. (2005) (54)
The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma (2012) (54)
Megakaryoblastic leukemia presenting as acute myelofibrosis -- a study of four cases with the platelet-peroxidase reaction. (1981) (53)
Abnormalities of chromosome 7q and Tac expression in T cell leukemias. (1986) (51)
Acute myeloid leukaemia not otherwise categorised. . (2001) (51)
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia (2007) (51)
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL (2008) (51)
Histopathology of the Spleen in T-Cell Large Granular Lymphocyte Leukemia and T-Cell Prolymphocytic Leukemia: A Comparative Review (2005) (51)
Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. (2003) (50)
High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. (1999) (50)
Hepatosplenic gamma delta T-cell lymphoma. A distinctive aggressive lymphoma type. (1995) (50)
Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH (2007) (49)
Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. (1990) (49)
A Distinctive Aggressive Lymphoma Type (1995) (49)
Translocation t(2;7)(p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. (2002) (48)
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. (2004) (47)
Transformation of T‐cell large granular lymphocyte leukaemia into a high‐grade large T‐cell lymphoma (2001) (46)
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence (2011) (46)
Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes (2003) (45)
Diagnostic issues in chronic lymphocytic leukaemia (CLL). (2010) (45)
Hairy cell leukaemia-variant: Disease features and treatment. (2015) (45)
FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias (1999) (44)
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns (2010) (43)
The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH (1999) (43)
Guide-lines for near patient testing: haematology. (1995) (42)
Adult T‐Cell leukemia/lymphoma: A working point‐score classification for epidemiological studies (1994) (42)
The 2017 WHO update on mature T‐ and natural killer (NK) cell neoplasms (2018) (42)
A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty (2010) (41)
Guidelines for the enumeration of CD4+ T lymphocytes in immunosuppressed individuals. CD4+ T lymphocyte Working Party. Members of the General Haematology Task Force of BCSH. (1997) (41)
Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. (2003) (41)
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele (2012) (41)
Alpha, beta and gamma T-cell receptor genes: rearrangements correlate with haematological phenotype in T cell leukaemias. (1987) (41)
Translocations t(14;18) and t(8;14) with rearranged bcl-2 and c-myc in a case presenting as B-ALL (L3). (1991) (40)
Functional properties of neoplastic T cells in adult T cell lymphoma/leukemia patients from the Caribbean. (1984) (40)
Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia (1999) (39)
Lymphopain, a cytotoxic T and natural killer cell-associated cysteine proteinase (1998) (39)
High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia (2011) (39)
Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use (2014) (37)
Splenectomy in lymphoproliferative disorders: a report on 70 cases and review of the literature. (1993) (37)
CD52 expression in T-cell large granular lymphocyte leukemia – Implications for treatment with alemtuzumab (2005) (36)
ATM mutations are rare in familial chronic lymphocytic leukemia. (2002) (36)
Isolated Bone Marrow Involvement in Diffuse Large B Cell Lymphoma: A Report of Three Cases with Review of Morphological, Immunophenotypic and Cytogenetic Findings (2004) (36)
Assessment of fl udarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial (2007) (36)
Myelodysplastic syndromes: introduction. (2001) (36)
The laboratory diagnosis of malaria (1997) (36)
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures (2009) (36)
Differential diagnosis in chronic lymphocytic leukaemia. (2007) (35)
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia (2018) (35)
B-ly-7, a monoclonal antibody reactive with hairy cell leukemia, also defines an activation antigen on normal CD8+ T cells. (1990) (34)
Leukaemia as a manifestation of large cell lymphoma (1991) (34)
Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia? (1997) (33)
Prolymphocytic Leukemia of B- and T-Cell Types (1984) (33)
Precursor T lymphoblastic leukaemia/lymphoblastic lymphoma. (Precursor T-cell acute lymphoblastic leukaemia). . (2001) (32)
Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. (2008) (32)
The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial (2016) (32)
Alemtuzumab in T-cell lymphoproliferative disorders. (2006) (32)
Prognostic Factors in the UK LRF CLL4 Trial. (2005) (31)
The P2X7 receptor gene A1513C polymorphism does not contribute to risk of familial or sporadic chronic lymphocytic leukemia. (2004) (31)
Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. (2000) (30)
Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene (2002) (30)
Fludarabine, Cyclophosphamide and Mitoxantrone in Relapsed or Refractory Chronic Lymphocytic Leukemia and Low Grade Non-Hodgkin's Lymphoma (2004) (30)
Fine-scale mapping of the 6p25.3 chronic lymphocytic leukaemia susceptibility locus. (2010) (30)
Relationship of T leukaemias with cerebriform nuclei to T‐prolymphocytic leukaemia: a cytogenetic analysis with in situ hybridization (1997) (30)
Acute myeloid leukaemia: Introduction. . (2001) (30)
NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease (2015) (30)
Functional Analysis of the ATM-p53-p21 Pathway in the LRF CLL4 Trial: Blockade at the Level of p21 Is Associated with Short Response Duration (2012) (30)
CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. (2002) (30)
Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia. (2009) (30)
Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia (2006) (29)
Response to Therapy and Survival in CLL Is Influenced by Genetic Markers. Preliminary Analysis from the LRF CLL4 Trial. (2004) (29)
B cell prolymphocytic leukaemia (B-PLL) with complex karyotype and concurrent abnormalities of the p53 and c-MYC gene (1999) (28)
Best Practice in Lymphoma Diagnosis and Reporting (2012) (28)
Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. (2005) (28)
p53 and mdm2 in mantle cell lymphoma in leukemic phase. (2002) (26)
MTHFR polymorphisms and risk of chronic lymphocytic leukemia. (2004) (25)
Chromosomal imbalances in familial chronic lymphocytic leukaemia: a comparative genomic hybridisation analysis (2002) (25)
Near-tetraploid acute myeloid leukemias: an EGIL retrospective study of 25 cases (2006) (24)
Drug cross‐resistance and therapy‐induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing (2009) (24)
Persistent polyclonal B-cell lymphocytosis. (1994) (23)
Persistent polyclonal B‐cell lymphocytosis in identical twins (1997) (23)
High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia (2006) (23)
Trisomy 12 in chronic lymphocytic leukaemia. (1996) (22)
Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier (2017) (22)
Molecular cytogenetic analysis in splenic lymphoma with villous lymphocytes: frequent allelic imbalance of the RB1 gene but not the D13S25 locus on chromosome 13q14. (1998) (22)
Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia (2002) (21)
Expression of TIA-1 and TIA-2 in T cell malignancies and T cell lymphocytosis. (1996) (21)
Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). (2012) (21)
Pentostatin and Cladribine in Hairy Cell Leukemia- a Retrospective Comparison of a Large Series with Long Follow up. (2004) (21)
Immunophenotype Changes and Loss of CD52 Expression in Two Patients with Relapsed T-cell Prolymphocytic Leukaemia (2001) (21)
Splenic marginal zone lymphoma: disease features and management (2013) (21)
Expression of Ki-67 nuclear antigen in B and T cell lymphoproliferative disorders. (1992) (21)
Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation (2012) (20)
Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options (2017) (20)
New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. (2002) (20)
Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). (2005) (19)
Contribution of immunophenotype in the diagnosis and classification of haemopoietic malignancies. (1995) (19)
Splenic marginal zone lymphoma with and without villous lymphocytes (2007) (19)
An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors (2015) (19)
T‐cell prolymphocytic leukaemia: antigen receptor gene rearrangement and a novel mode of MTCP1 B1 activation (2000) (18)
Hepatosplenic T cell lymphoma responsive to 2′‐deoxycoformycin therapy (2010) (18)
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. (1991) (17)
Isolated central nervous system involvement in adult T‐cell lymphoma/leukaemia (2005) (17)
Sezary cell-like leukemia: a distinct type of mature T cell malignancy. (1990) (17)
The spectrum of chronic lymphoproliferative disorders in Hong Kong. A prospective study (1997) (17)
Synchronous Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia and Melanoma in a Single Lymph Node (2010) (17)
Farage, a Novel Early B Cell Lymphoma Cell Line with Trisomy 11 (1992) (17)
Fludarabine in lymphoproliferative disorders: the Royal Marsden Hospital experience. (1994) (17)
A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma (2018) (16)
Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. (2005) (16)
Report of the second international symposium on HTLV in Brazil. (1994) (16)
Acute erythroid leukemia (M6): outcome of bone marrow transplantation. (1999) (16)
Acute myeloid leukaemia with multilineage dysplasia. . (2001) (16)
Granulomatous slack skin disease – disease features and response to pentostatin (2003) (15)
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on (2019) (15)
Refractory cytopenia with multilineage dysplasia (2001) (15)
Childhood near‐tetraploid acute lymphoblastic leukemia: an EGIL study on 36 cases (2010) (15)
Adult T-cell lymphoma/leukemia in a Caribbean patient: cytogenetic, immunologic, and ultrastructural findings. (1984) (14)
Cutaneous Mycobacterium chelonae infection in chronic lymphocytic leukaemia. (2007) (14)
Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia. (2005) (14)
Aberrant rearrangements within the immunoglobulin heavy chain locus in hairy cell leukemia. (1994) (14)
Prolymphocytic leukemias. (2006) (14)
Response to cyclosporine in a patient with disseminated granuloma annulare associated with CD4+/CD8+(dim)/CD56+ large granular lymphocytic leukemia. (2002) (13)
Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation (2008) (13)
Cd8+/vβ5.1+ large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2‐deoxycoformycin. (2002) (13)
Acute myelomonocytic leukemia with t(10;11)(p13;q23): Heterogeneity of breakpoints at 11q23 and association with recombinase activation (1994) (13)
Low frequency of ras oncogene mutations in Philadelphia-positive acute leukemia and report of a novel mutation H61 Leu in a single case. (1992) (12)
Refractory anaemia with ringed sideroblasts (2001) (12)
T-cell chronic lymphocytic leukaemia: the spectrum of mature T-cell disorders. (1988) (12)
Signet-ring cells in a Waldenström's Macroglobulinaemia. (1998) (12)
Immunological, ultrastructural and molecular features of unclassifiable acute leukaemia. (1993) (12)
Chronic T-cell lymphoproliferative disorders. (2002) (12)
HTLV-I positive adult T-cell leukaemia/lymphoma (ATLL) in Chile. (1994) (11)
Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021? (2021) (11)
Acute myeloid leukaemias and myelodysplastic syndromes, therapy related. (2001) (11)
DNA Genotypic Conservation During Phenotypic Switch from T-cell Acute Lymphoblastic Leukaemia to Acute Myeloblastic Leukaemia. (1989) (11)
Chimeric Matrix Proteins Encoded by Defective Proviruses with Large Internal Deletions in Human T-Cell Leukemia Virus Type 1-Infected Humans (2000) (11)
Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia (2010) (11)
A t(8;14)(q24;q32) in a T-lymphoma/leukemia of CD8+ large granular lymphocytes. (1987) (10)
An Atlas of Investigation and Diagnosis (2010) (10)
Increased sex concordance of sibling pairs with chronic lymphocytic leukemia (2004) (10)
Instability of CAG-trinucleotide Repeats in Chronic Lymphocytic Leukemia (2002) (10)
Establishing a KSHV1 Cell Line (BCP-1) From Peripheral Blood and Characterizing Its Growth in Nod/SCID Mice (1998) (10)
Morphological heterogeneity of Leu7, Leu11 and OKM1 positive lymphocyte subsets: an ultrastructural study with the immunogold method. (1987) (10)
The role of cytology, cytochemistry, immunophenotyping and cytogenetic analysis in the diagnosis of haematological neoplasms. General Haematology Task Force of the BCSH. (1996) (10)
Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution (2021) (9)
Atypical Lymphocytes in B-Cell Chronic Lymphocytic Leukemia and Trisomy 12 Studied by Conventional Staining Combined with Fluorescence In Situ Hybridization (2000) (9)
Addition of Anti-Viral Therapy to Chemotherapy Improves Overall Survival In Acute and Lymphomatous Adult T-Cell Leukaemia/Lymphoma (ATLL) (2010) (9)
Common variation at 6 p 21 . 31 ( BAK 1 ) influences the risk of chronic lymphocytic leukemia * (2012) (9)
Pregnancy improves neutropenia in T‐cell large granular lymphocyte leukaemia (2005) (9)
Clinical and biological diversity of splenic marginal zone lymphoma (2009) (9)
An unusual form of persistent polyclonal B lymphocytosis in an infant (2000) (8)
Establishing a KSHV 1 Cell Line ( BCP-1 ) From Peripheral Blood and Characterizing Its Growth in Nod / SCID Mice (1998) (8)
Novel and emerging drugs for rarer chronic lymphoid leukaemias. (2012) (8)
Annexin A1 expression in a splenic diffuse red pulp small B‐cell lymphoma: report of the first case (2013) (8)
Prolonged treatment response in aggressive natural killer cell leukemia (2005) (8)
Clinical features and management of non-gastrointestinal non-ocular extranodal mucosa associated lymphoid tissue (ENMALT) marginal zone lymphomas. (2017) (8)
The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry (2012) (8)
Morphological and immunophenotypical characterization of Japanese B-cell lymphocytic leukemia. (1994) (8)
Immunohistochemical distinction of haematogones from B lymphoblastic leukaemia/lymphoma or B‐cell acute lymphoblastic leukaemia (B‐ALL) on bone marrow trephine biopsies: a study on 62 patients (2011) (8)
Over 30% of Patients with Splenic Marginal Zone Lymphoma Express Distinctive Antigen Receptors Utilizing a Single Immunoglogulin Variable Gene: Implications for the Origin and Selection of the Neoplastic Cells (2010) (7)
Predictive Biomarkers and Personalized Medicine Functional Analysis of the ATM-p 53-p 21 Pathway in the LRF CLL 4 Trial : Blockade at the Level of p 21 Is Associated with Short Response Duration (2012) (7)
[Chronic lymphoproliferative syndromes in Chile. A prospective study in 132 patients]. (2003) (7)
First report of fludarabine in gamma‐heavy chain disease (1994) (7)
Recurrent pure red cell aplasia in a hepatorenal transplant recipient with chronic parvovirus B19 infection (2016) (7)
Higher expression levels of activation-induced cytidine deaminase distinguish hairy cell leukemia from hairy cell leukemia-variant and splenic marginal zone lymphoma (2010) (7)
Absence of HTLV‐I/II in T‐prolymphocytic leukaemia (1998) (7)
The P 2 X 7 Receptor Gene A 1513 C Polymorphism Does Not Contribute to Risk of Familial or Sporadic Chronic Lymphocytic Leukemia (2004) (6)
Alemtuzumab for Chronic Lymphocytic Leukemia with and without p53 Deletions. (2004) (6)
Acute erythroid leukaemias (2011) (6)
Clinico‐biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation (2021) (6)
Alemtuzumab Administered by Subcutaneous Route Is Less Effective Than Intravenous Route for First Line Therapy of T-Cell Prolymphocytic Leukaemia: Results of a Pilot Study (UKCLL05) (2008) (6)
A novel human macrophage-activating factor: Distinction from interferon-γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GMCSF) (1988) (6)
Splenic marginal zone lymphoma: a review of the clinical presentation, pathology, molecular biology, and management (2014) (6)
p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia. (1999) (6)
Refractory anaemia with excess blasts. (2001) (6)
Gender as a Prognostic Factor in CLL. Biological Pointers to the Improved Outcome of Women. (2004) (6)
Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group) (2010) (6)
Mutational Status of the TP53 Gene as a Predictor of Response and Survival in CLL Patients with and without 17p Deletion (2008) (6)
Is T-cell CLL a disease entity? (1996) (6)
Bilineal acute leukemia of B and T lineage with a novel translocation t(9;17)(p11;q11). (1997) (5)
T‐Cell Lymphoproliferative Disorders (2010) (5)
Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group). (2006) (5)
Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif (2002) (5)
Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma (2018) (5)
T-Cell Lymphoproliferative Disorders: Classification, Clinical and Laboratory Aspects (1998) (5)
Clinical and laboratory features of adult T-cell leukaemia lymphoma in Barbados. (1996) (5)
Clinical Outcome of Stem Cell Transplantation(SCT) in Patients with T Cell Prolymphocytic Leukaemia(T-PLL) Previously Treated with Alemtuzumab: A Multicentre Experience. (2005) (5)
Combinations of ZAP-70, CD38 and IgVH Mutational Status as Predictors of Time to First Treatment in CLL. (2005) (4)
A subset of mantle cell lymphoma exhibits stable disease and correlates with mutated VH genes and low CD38 expression (2001) (4)
Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study (2018) (4)
Teaching Cases from the Royal Marsden (1993) (4)
THE NATURE OF T‐CHRONIC LYMPHOCYTIC LEUKAEMIA (1986) (4)
Proliferative Hairy Cell Leukaemia (HCL-v) Resistant to Alpha-Interferon: Clinical, Diagnostic and In-Vitro Cellular Characteristics. (1990) (4)
The first report of familial adult T‐cell leukaemia lymphoma in the United Kingdom (1995) (4)
The WHO classification of mature T-cell leukemias. Authors' reply (2004) (4)
T lymphocyte subsets and colony growth in hairy-cell leukemia (1982) (4)
A matter of life or early death in CLL: do serum immunoglobulin levels really count? (2016) (4)
Teaching cases from the Royal Marsden and St Mary's Hospitals. Case 13: an orbital mass in a young girl. (1998) (4)
Genetic variation in CXCR 4 and risk of chronic lymphocytic leukemia (2009) (3)
Case 33. Diagnostic difficulty in a patient with acute leukemia (2007) (3)
Successful treatment of hairy cell leukemia variant with obinutuzumab (2021) (3)
Follicular Lymphoma. A Series of 11 Patients with Minimal or no Treatment and Long Survival (2000) (3)
Teaching cases from the Royal Marsden Hospital. Case 7: an east African with fever. (1993) (3)
Immunoblastic transformation of a Sezary syndrome in a black Caribbean patient without evidence of HTLV-I. (1995) (3)
B- Prolymphocytic Leukemia Shows Heterogeneous IgVH Mutational Status and Expression of ZAP-70 and CD38. (2004) (3)
Multinucleated giant myeloma cells after failure of daratumumab therapy (2018) (3)
Teaching Cases from the Royal Marsden and St Mary's Hospitals Case 25. A Young Boy with Massive Bilateral Renal Enlargement (2004) (3)
Teaching cases from the Royal Marsden and St Mary's Hospitals. Case 14: persistent lymphocytosis in a middle aged smoker. (1998) (3)
p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53 deletion and resistance to fludarabine (2010) (3)
Bone Marrow Lymphoid Infiltrates (2012) (3)
Contribution ofimmunophenotype inthe diagnosis andclassification ofhaemopoietic malignancies (1995) (3)
Epstein‐Barr virus negative large B‐cell lymphoma during long term immunomodulatory therapy for T‐cell large granular lymphocytic leukaemia (2010) (2)
Case 17: Essential thrombocythaemia with inversion 3 terminating in acute leukaemia. (1998) (2)
Non-Hodgkin's lymphoma (2000) (2)
A novel human macrophage-activating factor: distinction from interferon-gamma (IFN-gamma) and granulocyte-macrophage colony-stimulating factor (GMCSF). (1988) (2)
Different IGH Rearrangement and Somatic Hypermutation Patterns in Hairy-Cell Leukemia, Hairy-Cell Leukemia Variant and Splenic Marginal Zone Lymphoma. (2007) (2)
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility ‘counts’ even more (2016) (2)
Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System (2011) (2)
Intraclonal diversity in a Sezary syndrome with a differential response to 2‐deoxycoformycin of the two lymphoma cell populations (2002) (2)
1,25-DIHYDROXYVITAMIN D3 AND MYELOFIBROSIS (1984) (2)
Biological and prognostic methods of chronic lymphocytis leukemia (CLL). (2002) (2)
Quantitative expression of CD 23 and its ligand CD 21 in chronic lymphocytic leukemia (2000) (2)
Rituximab, Either As Single Agent or in Combination, Is Superior to Other Treatments in Terms of Response Rate and Progression-Free Survival (PFS) in Patients with Splenic Marginal Zone Lymphoma (SMZL) (2011) (2)
High Incidence of Myelodysplasia and Secondary Leukemia in the UK MRC Pilot Study of Autografting in Chronic Lymphocytic Leukemia. (2005) (2)
[Acute myeloid leukemia MO: clinical and laboratory characteristics]. (1997) (2)
Teaching cases from the Royal Marsden and St Mary's Hospitals. Case 15: uterine mass in an asymptomatic female. (1998) (2)
Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin? (2020) (2)
Predicting time to first treatment in early stage CLL: scores, values and comparative prognostic models (2017) (2)
High Grade Transformation in Splenic Marginal Zone Lymphoma: A Description of a Series of 8 Cases. (2006) (2)
Characterisation of TP 53 abnormalities in chronic lymphocytic leukaemia (2004) (2)
Recent advances in understanding small B-cell leukaemias and lymphomas (2004) (2)
Minimal residual disease in children with acute lymphoblastic leukaemia (1998) (2)
t(2;5) Associated with a Histiocytic-Monocytic Neoplasm (2001) (2)
A death from Langerhans cell histiocytosis and tuberculosis in 18th Century Hungary - what palaeopathology can tell us today (2006) (1)
ZAP-70 Expression in Chronic Lymphocytic Leukemia: Correlation with Clinical and Biological Features. (2004) (1)
Myelodysplastic syndromes associated with isolated del(5q) chromosome abnormality ("5q- syndrome"). . (2001) (1)
DEFECTIVE HTLV-1 PROVIRUSES WITH LARGE INTERNAL DELETIONS ARE CODING FOR CHIMERIC PROTEINS (1999) (1)
Clinical and economic benefits of using pegfilgrastim post autologous stem cell transplant (2010) (1)
Long-Term Follow-up of 228 Hairy Cell Leukemia Patients Treated with Pentostatin or Cladribine with 15.4 Years Median Time from Diagnosis. (2008) (1)
Gemcitabine, cisplatin and methylprednisolone (GEM-P) in patients with T-cell lymphoma: Results from The Royal Marsden Hospital. (2006) (1)
Classification of acute leukemias: reply from EGIL to Dr van Dongen. (1996) (1)
Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile (2021) (1)
Ultrastructural Analysis of B- and T-Lymphocyte Subsets with the Immunogold Technique (1984) (1)
Large B‐cell lymphoma presenting with lytic bone lesions and hypercalcaemia (1988) (1)
Is TCL1 overexpression a good or a bad player in mantle cell lymphoma? (2015) (1)
[Persistent polyclonal B-cell lymphocytosis: benign disease or prelymphoma?]. (2011) (1)
The spleen, bone marrow and blood (2012) (1)
T-CELL LEUKAEMIAS WITH "HELPER" PHENOTYPE IN ADULTS (1985) (1)
Splenic Lymphoma With Villous Lymphocytes: Analysis (2002) (1)
High Dose Methylprednisolone and Rituximab Is an Effective Therapy in Advanced Refractory Chronic Lymphocytic Leukaemia Resistant to Fludarabine Therapy. (2007) (1)
Chapter 14 – Immunophenotyping (2006) (1)
Deep-Sequencing Reveals the Molecular Landscape of Splenic Marginal Zone Lymphoma: Biological and Clinical Implications (2014) (1)
Clonal Selection in the Ontogeny and Evolution of Splenic Marginal Zone Lymphoma Confirming the Existence of Distinct Molecular Subtypes (2012) (1)
Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment (2022) (1)
Pathology of primary splenic B-cell lymphomas: a review (2020) (1)
Comparison of IgH Gene Rearrangement Configuration between Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia Variant (HCL-v). (2005) (1)
Microsatellite instability indicative of defects in the major mismatch repair genes is rare in patients with B-cell chronic lymphocytic leukemia: Evaluation with disease stage and family history (2007) (1)
lymphocytic leukemia ) influences the risk of chronic BAK1 (2012) (1)
European Leukemianet (ELN) Project Diagnostic Platform (WP10): Final Results of the First Study of the European Morphology Consensus Panel. (2008) (1)
Teaching cases from the Royal Marsden and St Mary's Hospital case 29: Striking generalized lymphadenopathy in 'acute myeloid leukemia' (2005) (1)
Atlas of Genetics and Cytogenetics in Oncology and Haematology (2011) (1)
The Spectrum of T-cell and Natural Killer – Large Granular Lymphocytic Proliferations (2010) (1)
Royal Marsden teaching cases. An elderly man with weight loss and anaemia. (1996) (1)
Hairy cell leukemia (HCL) and hairy cell leukemia variant (HCL-V) (2011) (1)
Immunophenotyping (Chapter 14) (2001) (0)
The challenge of unavailable IGH mutational status in CLL in resource-limited settings (2020) (0)
lymphoma/leukemia patients from the Caribbean Functional properties of neoplastic T cells in adult T cell (2011) (0)
Drug points: Fatal erythroderma associated with pentostatin (1999) (0)
B- Cell Chronic Lymphocytic Leukaemia Complicated by Aggressive T-Cell Lymphoma: Clinical and Molecular Analysis of a Rare Variant of Richter’s Syndrome. (2005) (0)
Brief report Common variation at 6p21.31 ( BAK1 ) inﬂuences the risk of chronic lymphocytic leukemia (2012) (0)
Mixed-phenotype acute leukemia: disease features and outcome. (2011) (0)
Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia.: 51st Annual Meeting of the American-Society-of-Hematology (2009) (0)
Morphological heterogeneity ofLeu7, LeullandOKM1 positive lymphocyte subsets: anultrastructural study withtheimmunogold method (1987) (0)
Allelic loss of 13q14 at the D13S25 locus but not RB1 or trisomy 12 is an independent prognostic factor on survival in chronic lymphocytic leukemia (1997) (0)
Correlation between TP53 Deletion and Protein Overexpression in Chronic Lymphocytic Leukaemia and Its Impact on Prognostic. (2007) (0)
Immunophenotyping as a diagnostic and prognostic tool (2010) (0)
Professor Daniel Catovsky 19 September 1937-2 December 2022. (2023) (0)
Intra-Lineage Phenotypic Switch in T-Cell Prolymphocytic Leukemia. (2004) (0)
the MRC Pilot Study safe and achieves a high percentage of molecular responses. Results of Autografting for younger patients with chronic lymphocytic leukaemia is (2013) (0)
High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Reveals Novel Genomic Lesions in Hairy Cell Leukaemia and Hairy-Cell Leukaemia Variant (2008) (0)
Impact of molecular genetics and immunoglobulin mutational status in prognosis and management of chronic lymphocytic leukaemia. (2003) (0)
Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors. (2023) (0)
The assessment of minimal residual disease in chronic lymphocytic leukaemia: comparison of multi-colour flow cytometry and bone marrow trephine biopsy (2012) (0)
defines an activation antigen on normal CD8+ T cells (see comments) B-ly-7, a monoclonal antibody reactive with hairy cell leukemia, also (2011) (0)
Teaching Cases from The Royal Marsden and St Mary's Hospitals. Case 22: An Unusual Cause of Lymphocytosis (2002) (0)
B-cell prolymphocytic leukemia and hairy cell leukemia: new advances in biology and treatment (2012) (0)
Campath 1H (CD52) antibody therapy in chronic lymphoid disorders. (2002) (0)
T-cell chronic lymphoproliferative disorders. (2003) (0)
Isolated cutaneous lymphomatous form of adult T‐cell leukaemia/lymphoma (2019) (0)
Cytometric Analysis of Cell Phenotype and Function, First edition. Edited by Desmond A. McCarthy and Marion G. Macey. Cambridge University Press, Cambridge, UK, 2001. Pp. 413. £95. (2002) (0)
Gene Expression Reveals Two Distinct Biological Groups within T-Cell Prolymphocytic Leukaemia. (2005) (0)
Teaching Cases from the Royal Marsden Hospital Case 1: a young man with petechiae and splenomegaly. (1991) (0)
CHILDHOOD BIPHENOTYPIC LEUKAEMIA : THE ROYAL MARSDEN EXPERIENCE. 160 (1997) (0)
Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis (2019) (0)
Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms (2015) (0)
B-lymphocyte expansion Inherited predisposition to CLL is detectable as sub-clinical monoclonal (2013) (0)
12. PROLYMPHOCYTIC LEUKEMIA (1984) (0)
Teaching Cases from the Royal Marsden Hospital Case 2: a young man with bruising. (1991) (0)
Teaching Cases from the Royal Marsden Hospital Case 3: a lymphoproliferative disorder of 17 years duration (1992) (0)
Combined aCGH and Mutational Analysis of CLL Patients with 17p Deletion. (2006) (0)
Orphan drugs for the treatment of hairy cell leukemia (2013) (0)
Gene Expression Profiling Classifies Splenic Marginal Zone Lymphoma and Hairy Cell Leukemia-Variant as Related Diseases That Are Distinct From Typical Hairy Cell Leukemia. (2009) (0)
Myelodysplastic syndromes, unclassifiable. . (2001) (0)
The Role of the Monoclonal Antibody Anti-Myeloperoxidase (anti-MPO) in the Diagnosis and Classification of Acute Leukaemias (2000) (0)
Genome-Wide Profiling of DNA Copy Number Variation in CLL Cases Lacking 17p- (TP53) or 11q- (ATM) Abnormalities Selected from the CLL4 Study (2008) (0)
Genomewide Linkage Analysis of Chronic Lymphocytic Leukemia by Use of a High-Density Single Nucleotide Polymorphism Assay Containing 11,555 Markers. (2004) (0)
Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era? (2015) (0)
Unraveling the genetics of transformed splenic marginal zone lymphoma. (2023) (0)
T-Cell Membrane CD45RA (2H4) and CD45RO (UCHL1) Determinants: II, Aberrant HLA-ABC Expression by CD45RA and CD45RO Cell Subpopulations of Mature CD4(+) T-Cell Leukaemias. (1991) (0)
Acknowledgement to referees (2006) (0)
Biphenotypic Acute Leukaemia (BAL) (2011) (0)
Leukaemic lymphoproliferative disorders. (2003) (0)
Mixed phenotype acute leukemia (MPAL): clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification Authors: (2011) (0)
Distinctive Patterns of Intraclonal Diversification In IGHV1-2*04 Immunoglobulin Receptors of Patients with Splenic Marginal Zone Lymphoma: A of Ongoing Interactions with Antigen? (2011) (0)
VH Gene Analysis in Splenic Marginal Zone Lymphoma Identifies Patients with Structurally Similar B Cell Receptors but Does Not Provide Prognostic Information. (2006) (0)
Report of the International Splenic Lymphoma Study Group meeting held in 2019 in Barcelona, Spain (2020) (0)
Associations between Chromosomal Aberrations and Functional Impairment of the P53 Pathway in Chronic Lymphocytic Leukaemia. (2004) (0)
Recent Advances in the Cytobiology of Leukemias * DEFINITION OF ACUTE BIPHENOTYPIC LEUKEMIA (0)
A phase I trial of the PARP inhibitor olaparib in patients with relapsed or refractory Chronic Lymphocytic Leukaemia, T-Prolymphocytic Leukaemia or Mantle Cell Lymphoma (2018) (0)
B-Cell Prolymphocytic Leukemia (B-PLL) and Chronic Lymphocytic Leukemia (CLL) Express Distinct Genomic Profiles. (2005) (0)
Teaching cases from the Royal Marsden Hospital. Case 16: T-cell non Hodgkin's lymphoma associated with hypercalcaemia in a black Caribbean. (1998) (0)
Antigenic phenotype of leukaemic progenitor cells (AML-CFU-L) in three cases of megakaryocytic leukaemia (1986) (0)
Molecular Cytogenetic Analysis in Splenic Lymphoma with Vifious Lymphocytes : Frequent Allelic Imbalance of the RBJ Gene but not the D 13 S 25 Locus on Chromosome 13 q 141 (2006) (0)
through analysis of IgVH gene usage and mutation status in familial Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) (2013) (0)
Hairy Cell Leukemia (2017) (0)
Management of infectious complications in chronic lymphocytic leukemia. (2009) (0)
Author response for "IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FIVE YEARS ON" (2019) (0)
Immunoglobulin Gene Translocations Are Frequent in Unclassifiable CD5+ Small B-Cell Leukemias and in Particular, a Novel Subtype Characterised by t(14;19)(q32;q13) and Deregulation of BCL3 Is Described. (2007) (0)
Abnormalities in B-Cell Prolymphocytic (1997) (0)
CLL and CML sometimes meet and circulate together (2019) (0)
The Histone Deacetylase 9 Gene Is Regulated by Multiple Promoters and Expresses Lymphoid-Specific Isoforms. (2004) (0)
Teaching Cases from the Royal Marsden Hospital Case 4: fever, hepatic dysfunction and cytopenia (1992) (0)
Isolated bone marrow amyloid light chain amyloidosis coexisting with multiple myeloma (2023) (0)
Whole Genome Sequencing of B-Cell Neoplasms with t(14;19)(q32;q13) Reveals Different Entities (2021) (0)
Bacterial Artificial Chromosome (BAC) Array CGH Study of B-CLL Patients with 17p13 Deletion. (2005) (0)
Teaching cases from the Royal Marsden Hospital. Case 8: a Japanese patient with leukaemia and headache. (1993) (0)
Monoclonal antibody bi 3c 5 of use in the classification of acute leukemias (1985) (0)
Chronic lymphocytic leukaemia (2007) (0)
Leukaemias and mature T cells (Chapter 43) (2001) (0)
susceptibility in familial chronic lymphocytic leukemia related genetic - Linkage analysis for major histocompatibility complex (2013) (0)
Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia – response to Benz et al (2010) (0)
Teaching cases from the Royal Marsden Hospital. Case 6: a man with a large cervical mass. (1992) (0)
T-Cell large granular lymphocytic leukemia, T-cell prolymphocytic leukaemia and aggressive natural-killer cell leukemia/lymphoma. (2004) (0)
Treatment options for T-cell large granular lymphocyte leukemia - A case series with review of the literature (2007) (0)
Classification of T-Cell disorders (2011) (0)
Increased Frequency of Constitutional PathogenicATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role. (2009) (0)
Is ibrutinib the gold standard for therapy – naive elderly patients with CLL? (2022) (0)
Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial (2011) (0)
Bone Marrow Involvement in Primary Mature B and T Cell Leukemias (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Estella Matutes?

Estella Matutes is affiliated with the following schools:

Estella Matutes's Academic­Influence.com Rankings

Why Is Estella Matutes Influential?

Estella Matutes's Published Works

Published Works

What Schools Are Affiliated With Estella Matutes?

Estella Matutes's AcademicInfluence.com Rankings